Jinarc (Tolvaptan)

Tolvaptan selectively blocks vasopressin V2 receptors in the kidney’s collecting ducts. This antagonism reduces the effect of antidiuretic hormone, allowing excess water to be excreted as free water while retaining electrolytes, which limits cystic fluid accumulation in ADPKD.

The dosage of Jinarc is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, laboratory values, and response to therapy. Specific dosing regimens are not disclosed publicly.

Safety data for Tolvaptan in pregnancy and lactation are limited. It is generally contraindicated unless the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception while on therapy.

To request Jinarc, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Jinarc (Tolvaptan) is the only approved oral vasopressin V2 receptor antagonist for ADPKD, directly targeting cyst growth. Other management options focus on blood pressure control, pain relief, or supportive dialysis, but do not specifically slow cyst development like Tolvaptan.

Jinarc tablets should be stored at temperatures below 25 °C, in the original packaging, and protected from moisture. Keep the product out of reach of children and avoid exposure to direct sunlight or excessive humidity.

Jinarc is taken orally as a tablet, usually with a glass of water. The exact timing and frequency are set by the prescribing clinician, who may adjust the regimen based on liver‑function monitoring and patient tolerance.

The most serious risks include liver injury (elevated transaminases or hepatic failure), severe dehydration from excessive water loss, and hypernatremia. Patients should undergo regular liver‑function tests and maintain adequate fluid intake, reporting any signs of liver dysfunction promptly.

Jinarc should be avoided in patients with severe hepatic impairment, uncontrolled dehydration, or known hypersensitivity to Tolvaptan. It is also contraindicated in individuals who are pregnant or breastfeeding unless the prescriber determines that the benefits outweigh the risks.